[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometriosis-diagnosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometriosis-diagnosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,106,133,160,187],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100652600","deep-endometriosis-affecting-the-urogenital-tract-long-term-outcomes-and-impact-on-renal-function-100652600",false,"NCT07776574","Deep Endometriosis Affecting the Urogenital Tract: Long-term Outcomes and Impact on Renal Function","RENDO","Inclusion Criteria:• age ≥ 18 years;\n\n* hydronephrosis caused by DE-related ureteral stenosis;\n* for Group F: a history of surgical treatment of ureteral endometriosis (ureterolysis, ureteroureterostomy, UCNA) at our center at least 24 months previously;\n* for Group S: indication for surgical treatment because of hydronephrosis or clinically significant ureteral stenosis;\n* signed informed consent.\n\nExclusion Criteria:• pregnancy;\n\n* malignancy;\n* congenital uropathy;\n* other renal diseases;\n* inability to undergo dynamic renal scintigraphy (e.g., allergy to the radiopharmaceutical or severe comorbidities precluding the examination);\n* previous urinary tract surgery unrelated to ureteral endometriosis that could substantially confound the assessment of renal function.","FEMALE","18 Years",{"count":19,"type":20},20,"ESTIMATED","36 Months","OBSERVATIONAL","Endometriosis is a chronic estrogen-dependent disease characterized by the presence and growth of endometrium-like tissue outside the uterine cavity.\n\nThis ectopic endometrial tissue induces a chronic local and systemic inflammatory response, resulting in the most common manifestations of the disease: chronic pelvic pain, infertility, and pelvic adhesions. In deep endometriosis (DE), adhesions and infiltrative growth may damage adjacent organs.\n\nOverall, endometriosis affects approximately 10% of women of reproductive age. Its prevalence is higher among women with infertility (20-50%) and among patients with chronic pelvic pain (up to 90%).\n\nThe disease is usually categorized as superficial peritoneal, ovarian, or deep endometriosis (DE). Deep endometriosis is a progressive form of the disease that may affect organs beyond the pelvic cavity, including the urinary tract, alter their anatomy, and cause functional impairment.\n\nUrogenital involvement occurs in approximately 1-5.5% of all women with endometriosis; the prevalence is substantially higher among patients with DE, reaching 16-53% according to the available literature.\n\nWithin the urinary tract, the bladder is most commonly affected (70-85%), followed by the ureters (9-23%), kidneys (approximately 4%), and urethra (approximately 2%).\n\nUreteral endometriosis is therefore a relatively rare but clinically significant entity. It may be unilateral or bilateral, with a predominance of left-sided involvement.\n\nTwo basic forms are distinguished:\n\n* \"Extrinsic\" - ureteral stenosis caused by periureteral fibrosis and the presence of DE lesions without infiltration of the ureteral wall.\n* \"Intrinsic\" - ureteral stenosis caused by direct infiltration of the ureteral wall by endometriotic tissue.\n\nUreteral stenosis causes secondary hydronephrosis and, unless treated in a timely manner, may lead to a progressive loss of renal function.\n\nThe disease frequently remains asymptomatic for a prolonged period. Up to half of cases are diagnosed incidentally or only at an advanced stage, when renal damage is already irreversible.\n\nEarly detection and timely planning of surgical management are therefore essential for preserving renal function.\n\nThe main surgical procedures are:\n\n* ureterolysis - release of the ureter from fibrotic adhesions, preferred for the extrinsic form;\n* ureteroneocystostomy (UCNA) - indicated for the intrinsic form when the affected segment must be resected and the ureter reimplanted into the bladder;\n* ureteroureterostomy (ureteral anastomosis) - appropriate for the intrinsic form when, following resection, the distal ureteral segment is sufficiently long to allow anastomosis of healthy margins.\n\nDespite the clinical significance of the condition, prospective studies objectively evaluating the evolution of renal function after the individual types of surgical management of ureteral endometriosis are still lacking.\n\nA modern diagnostic strategy combining specialized ultrasound, dynamic renal scintigraphy (MAG3), and analysis of urinary biomarkers of tubular injury (KIM-1, CCL-2, L-FABP) enables earlier detection of renal dysfunction and more accurate monitoring of postoperative recovery. Identification of sensitive biomarkers of early renal injury and validation of an algorithm for their use could substantially improve decisions regarding the timing of surgery and subsequent postoperative follow-up.\n\nBased on our experience, some patients surgically treated for hydronephrosis caused by DE-related ureteral stenosis show persistent morphological changes on renal ultrasound and the manifestation of systemic conditions such as arterial hypertension during long-term follow-up. To date, no study has focused on the long-term follow-up of patients with ureteral DE and its potential consequences. The expected benefit of this study is to establish clear criteria for the indication of surgical treatment of ureteral endometriosis and to develop an evidence-based protocol for long-term follow-up.",[25,26,27],"Endometriosis","Endometriosis (Diagnosis)","Urinary Tract Diseases",[29,30,31],"deep infiltrated endometriosis","ureteral endometriosis","nephrectomy","RECRUITING","2026-08-17",{"date":35,"type":36},"2026-08-20","ACTUAL",{"date":38,"type":36},"2026-04-01",{"date":40,"type":20},"2029-07-01",{"name":42,"class":43},"Charles University, Czech Republic","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":60,"conditions":61,"keywords":78,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100647234","phase-1-fapi-pet-imaging---an-exploratory-study-100647234","NCT07705074","FAPI PET Imaging - An Exploratory Study","FAPI PET Imaging - a Multicentric Exploratory Evaluation","FAPIPET","Inclusion Criteria:\n\n* Written informed consent obtained and documented by the participant's signature.\n* Age ≥18 years at the time of consent.\n* Clinically established or suspected diagnosis or recurrence of an oncologic or non-oncologic disease as defined in chapter 7.1 of study protocol.\n* Availability of standard-of-care imaging (e.g., clinically established PET tracer or anatomical imaging such as CT\u002FMRI) to allow comparative evaluation.\n\nExclusion Criteria:\n\n* Severe claustrophobia that would preclude PET imaging.\n* Inability to remain still for the duration of the PET\u002FMR examination.\n* Current pregnancy or breastfeeding; no pregnancy test is required for women who are postmenopausal for ≥12 months or have undergone surgical sterilization, bilateral oophorectomy, or hysterectomy.\n* Previous hypersensitivity reactions to radiotracer administration\n* Inability to understand the study information, for example due to language barriers.\n* Subjects incapable of judgment (e.g. individuals under legal or medical incapacity).\n* Participants scheduled for PET\u002FMR imaging: Presence of MRI-incompatible metallic implants, electronic devices (e.g. pacemakers, cochlear implants), or other ferromagnetic foreign bodies.","ALL",{"count":55,"type":20},770,"INTERVENTIONAL",[58,59],"PHASE1","PHASE2","This study is testing a new imaging tracer called \\[18F\\]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions like fibrosis and sarcoidosis.\n\n\\[18F\\]FAPI-74 attaches to a protein found on cells that are active in tumors and areas of scarring or inflammation. This may help doctors see these areas more clearly than with imaging methods used today, especially in diseases where current scans do not work well.\n\nPeople who join this study will get one injection of the tracer into a vein, then have one PET\u002FCT or PET\u002FMR scan. This takes about 2 hours in total. Researchers will compare the results with imaging the participant already had as part of their regular care, such as other PET scans, CT, or MRI. No extra treatment is given, and no other visits are needed.\n\nThe study will take place at 5 hospitals in Switzerland and plans to include about 770 adults with a confirmed or suspected diagnosis of one of the conditions being studied. The main goal is to see how clearly the tracer shows up on the scan. Researchers will also look at whether this new scan changes how confident doctors feel about a diagnosis, or changes the patient's treatment plan.",[62,63,64,65,66,67,68,69,70,71,72,73,74,26,75,76,77],"Thyroid Pathology","Head and Neck Cancer (H&N)","Sinonasal Tract Tumor","Sarcoidosis","Thyroid Cancer","Breast Cancer","Hepatocellular Carcinoma (HCC)","Gastric Cancer (GC)","Pancreatic Cancer, Adult","Urothelial Carcinoma (UC)","Multiple Myeloma or Plasmacytoma","Mesothelioma","Hepatic Fibrosis","Lung Fibrosis","Neck Node Metastasis","Prostate Cancer (CRPC)",[79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94],"[18F]FAPI-74","Fibroblast Activation Protein","FAP-targeted imaging","PET\u002FCT","Radiotracer","Diagnostic imaging","Multicentric study","Radiopharmaceutical","FAPI","FAPI-74","nuclear medicine","University Hospital Zurich","swiss multicenter trial","Cancer-associated fibroblast imaging","oncologic imaging","non-oncologic imaging","NOT_YET_RECRUITING","2026-07-09",{"date":98,"type":36},"2026-07-15",{"date":100,"type":20},"2026-08",{"date":102,"type":20},"2029-09",{"name":104,"class":43},"Martin Huellner",5,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":113,"enrollmentInfo":114,"targetDuration":116,"studyType":22,"phases":4,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":132},"100636066","impact-of-endotest-on-patients-quality-of-life-a-cohort-study-100636066","NCT07560852","Impact of Endotest on Patients' Quality of Life: a Cohort Study","ENDOLIFE","Inclusion Criteria:\n\n* Women with a prescription for Endotest\n* Women aged 18 to 43\n* Who have dated and signed the consent form\n* Affiliated with the French healthcare system or covered by health insurance abroad\n\nExclusion Criteria:\n\n* Contraindications for the use of Endotest:\n\n  1. Current pregnancy;\n  2. Medical history of cancer or HIV infection;\n  3. Active infection at the time of saliva collection;\n* Significant difficulty reading and understanding the language of the country in which the participant is located.","43 Years",{"count":115,"type":20},20000,"16 Months","Ziwig Endotest® ('Endotest') is marketed in several countries, including Switzerland, which was the first country to make it available in 2022. Since February 2025, several French clinical investigation sites have been offering Endotest, developed by Ziwig, under the innovation funding. Initially, this innovation funding enabled 2,500 patients to be included in a clinical trial (ENDOBEST: ID-RCB 2024-A02092-45). Since the end of December 2025, it has been expanded and now covers a further 22,500 patients whose are not included in the trial. This medical device is based on Next-Generation Sequencing combined with analytical algorithms and enables the identification of endometriosis from a saliva sample. This non-invasive test aims to improve patient care by reducing diagnostic delays and guiding treatment strategies.\n\nDespite the available data on its diagnostic performance, the impact of Endotest on patients' quality of life, their emotional experience, their coping strategies, and their care pathways remains insufficiently documented. Indeed, the Endotest result (positive or negative) can significantly influence these various aspects. This cohort study aims to assess the impact of Endotest on patients' quality of life, primarily using validated self-report questionnaires and clinical data from medical records. By including a large sample of patients, this study aims to provide robust and generalisable data that will be useful for clinicians and patients themselves.",[119,26],"Patient With a Prescribed Endotest",[121],"endometriosis","2026-05-20",{"date":124,"type":36},"2026-05-26",{"date":126,"type":36},"2026-05-06",{"date":128,"type":20},"2029-07-31",{"name":130,"class":131},"ZIWIG","INDUSTRY",7,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":56,"phases":143,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":44},"100623232","impact-of-food-supplementation-on-quality-of-life-in-patients-with-endometriosis-and-pelvic-pain-100623232","NCT07393958","Impact of Food Supplementation on Quality of Life in Patients With Endometriosis and Pelvic Pain.","Experimental Study of Quality of Life in Patients With Endometriosis and Pelvic Pain Treated With Doliral Dietary Supplementation Versus Placebo.","ENDOLIRAL","Inclusion Criteria:\n\n* Women of reproductive age with diagnosed endometriosis stage I, II, or III, according to the American Society for Reproductive Medicine (ASRM) classification.\n* Women with a diagnosis of endometriosis confirmed by laparoscopy or, in the absence of laparoscopy, by magnetic resonance imaging (MRI) and\u002For ultrasound.\n* Presence of pelvic pain (VAS \\> 4) during the last three months.\n* No indication for surgical intervention at the time of inclusion in the study.\n* Patients who are able to provide informed consent.\n\nExclusion Criteria:\n\n* Patients under 18 years of age.\n* Use of analgesic or anti-inflammatory pharmacological treatment, except for ibuprofen at doses up to 600 mg\u002Fday or naproxen at doses up to 500 mg\u002Fday.\n* Surgery within the year prior to inclusion, performed for therapeutic purposes related to the pathology under study.\n* Initiation or discontinuation of hormone therapy within the three months prior to inclusion in the study.\n* Patients with known allergy or hypersensitivity to Doliral®.\n* Pregnant or breastfeeding patients.\n* Patients on sick leave: \\> 1 year, or With no intention of returning to work, or Undergoing a disability or permanent incapacity assessment process.",{"count":142,"type":20},60,[144],"NA","This study examines whether the food supplement Doliral can improve quality of life and reduce pelvic pain in women with endometriosis, compared with placebo, over several weeks.",[26],[148,149,150],"pain","QoL","food supplement","2026-02-27",{"date":153,"type":36},"2026-03-02",{"date":155,"type":36},"2026-02-26",{"date":157,"type":20},"2026-09-15",{"name":159,"class":131},"Arafarma Group, S.A.",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":184,"locationsCount":186},"100625839","observational-study-on-the-use-of-ultrasound-to-recognize-superficial-endometriosis-in-a-specific-area-of-the-pelvis-the-uterosacral-ligaments-100625839","NCT07427849","Observational Study on the Use of Ultrasound to Recognize Superficial Endometriosis in a Specific Area of the Pelvis (the Uterosacral Ligaments)","Ultrasound Diagnosis of Superficial Endometriosis of LUS (Uterosacral Ligaments): Definition of a Laparoscopically Validated Ultrasound Cut-off.","LUS","Inclusion Criteria:\n\n* patients who need to undergo gynecological surgery with a laparoscopic approach for benign pathology (endometriosis, uterine fibroids, adenomyosis, chronic pelvic pain, benign ovarian cysts) or non-advanced malignant pathology (stage I endometrium and cervix, stage I and II ovary).\n* patients who performed a level II gynecological ultrasound with an experienced operator in the preoperative pathway.\n* technical possibility of performing a transvaginal ultrasound and the patient's willingness to undergo such an investigation.\n* patients of childbearing age (18 - 50 years).\n* Signing of informed consent.\n\nExclusion Criteria:\n\n* presence of endometriosis deeply infiltrating the posterior compartment. This may interfere with the interpretation of uterosacral ligament (LUS) thickness as a specific marker of superficial endometriosis\n* technical impossibility of performing a transvaginal ultrasound (patient virgo, patient refusal).\n* incomplete ultrasound evaluation of the uterosacral ligaments for anatomical reasons or for the presence of endometriosis nodules from other sites with partial involvement of the LUS (uterosacral ligament).\n* advanced malignant disease (\\>Stage I for endometrium and cervix, \\> Stage II for ovary)\n* pelvic organ prolapse\n* PID or other pelvic inflammatory diseases\n* medical emergencies (ovarian torsion, hemoperitoneum)\n* postmenopausal patients\n* previous pelvic surgery","50 Years",{"count":170,"type":20},64,"An observational, prospective, multicenter study conducted on patients of childbearing age undergoing laparoscopic surgery for early-stage benign or malignant gynecological disease. The study does not include changes to the standard care pathway.",[26],[174,175,176,177],"ultrasound","gynecology","laparoscopic surgery","uterosacral ligaments","2026-02-23",{"date":180,"type":36},"2026-02-25",{"date":182,"type":36},"2026-02-17",{"date":100,"type":20},{"name":185,"class":43},"Casa di Cura Dott. Pederzoli",4,{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":56,"phases":196,"briefSummary":198,"conditions":199,"keywords":208,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":44},"100604083","phase-4-assessing-the-efficacy-of-indocyanine-green-for-ureter-identification-during-robot-assisted-surgery-in-advanced-stage-endometriosis-100604083","NCT07144904","Assessing the Efficacy of Indocyanine Green for Ureter Identification During Robot-Assisted Surgery in Advanced-Stage Endometriosis","A Side-Randomized, Self-Controlled Trial Assessing the Efficacy of Indocyanine Green Fluorescence Imaging for Intraoperative Ureter Identification During Robot-Assisted Single-Site Surgery in Advanced-Stage Endometriosis","Inclusion Criteria:\n\n* Stage III or IV endometriosis (rASRM classification)\n* Planned robotic transabdominal endometriosis excision with or without hysterectomy.\n\nExclusion Criteria:\n\n\\- Subjects who are part of a vulnerable population will be excluded including those who are prisoners, younger than 18 years old, pregnant, individuals with mental disabilities or cognitive impairment.",{"count":195,"type":20},40,[197],"PHASE4","The goal of this side-randomized, self-controlled trial, 1-site study is to explore the efficacy of Indocyanine Green Fluorescence (ICG) for Intraoperative Ureter Identification During Robot-Assisted Single-Site Surgery in Advanced-Stage Endometriosis.\n\nResearchers will perform temporary ureteral stent using indocyanine green fluorescence for intraoperative ureteral identification on either the left or right side of subjects who are undergoing a robotic assisted transumbilical resection of advanced endometriosis.\n\nParticipants will be randomized to receive ICG-assisted ureteral identification on either the left or right side. Randomization will be conducted using a computer-generated block randomization method.\n\nThe primary aim is to determine whether ICG-assisted ureter visualization can reduce operative time for endometriosis resection and ureterolysis, and minimize the risk of ureteral injury.\n\nSecondary objectives are to assess the feasibility and safety of temporary ureteral ICG stenting for intraoperative ureter identification in advanced endometriosis.",[200,201,202,203,26,204,205,206,207],"Indocyanine Green (ICG)","Robotic Surgical Procedure","Deep Infiltrating Endometriosis (DIE)","Endometriosis Pelvic","Endometriosis of the Cul-de-sac","Ureteral Stent Placement","Ureteral Injury","Endometriosis Ovaries",[209,210,121,211,212],"ureteral stent placement","indocyanine green","robotic surgery","ureteral identification","2025-08-20",{"date":215,"type":36},"2025-08-28",{"date":217,"type":20},"2025-10-01",{"date":219,"type":20},"2026-03-15",{"name":221,"class":43},"Baylor College of Medicine"]